Mutations in the KRAS gene have been identified in CH, which, in the context of liquid biopsy analysis in NSCLC, could prevent further genotyping efforts based on mutual exclusivity with other driver genes, potentially leading to missed detections of actionable alterations [69,70]. Here, KRAS is linked to non-small cell lung carcinoma.